- Home
- GDEN vs TYRA Comparison
GDEN vs TYRA Comparison
Compare GDEN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- TYRA
- Stock Information
- Founded
- GDEN 1998
- TYRA 2018
- Country
- GDEN United States
- TYRA United States
- Employees
- GDEN N/A
- TYRA N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- TYRA Health Care
- Exchange
- GDEN Nasdaq
- TYRA Nasdaq
- Market Cap
- GDEN 961.7M
- TYRA 812.7M
- IPO Year
- GDEN 1999
- TYRA 2021
- Fundamental
- Price
- GDEN $31.12
- TYRA $14.00
- Analyst Decision
- GDEN Strong Buy
- TYRA Strong Buy
- Analyst Count
- GDEN 6
- TYRA 5
- Target Price
- GDEN $37.33
- TYRA $31.00
- AVG Volume (30 Days)
- GDEN 315.0K
- TYRA 219.5K
- Earning Date
- GDEN 11-07-2024
- TYRA 11-07-2024
- Dividend Yield
- GDEN 3.21%
- TYRA N/A
- EPS Growth
- GDEN N/A
- TYRA N/A
- EPS
- GDEN 1.27
- TYRA N/A
- Revenue
- GDEN $733,305,000.00
- TYRA N/A
- Revenue This Year
- GDEN N/A
- TYRA N/A
- Revenue Next Year
- GDEN $2.28
- TYRA N/A
- P/E Ratio
- GDEN $24.55
- TYRA N/A
- Revenue Growth
- GDEN N/A
- TYRA N/A
- 52 Week Low
- GDEN $27.42
- TYRA $11.24
- 52 Week High
- GDEN $40.85
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- GDEN 36.06
- TYRA 32.68
- Support Level
- GDEN $32.62
- TYRA $14.65
- Resistance Level
- GDEN $33.59
- TYRA $15.55
- Average True Range (ATR)
- GDEN 1.03
- TYRA 0.72
- MACD
- GDEN -0.37
- TYRA 0.02
- Stochastic Oscillator
- GDEN 21.13
- TYRA 3.12
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).